Table 1 Characteristics of patients in the experimental and control groups for each outcome.
From: Risk factors of adverse pregnancy outcomes in patients with immunoglobulin A nephropathy
Hypertensive disorders of pregnancy (needed intravenous nicardipine) | Preterm delivery (delivered before 37 weeks of pregnancy) | |||
|---|---|---|---|---|
Case (n = 34) | Control (n = 263) | Case (n = 56) | Control (n = 237) | |
Age | ||||
Median (IQR) | 35 (31, 37) | 33 (29, 36) | 34 (30, 37) | 33 (29, 36) |
≤ 19 years | 0 (0%) | 4 (1.5%) | 0 (0%) | 4 (1.7%) |
20–34 years | 16 (47.1%) | 157 (59.7%) | 29 (51.8%) | 141 (59.5%) |
≥ 35 years | 18 (52.9%) | 102 (38.8%) | 27 (48.2%) | 92 (38.8%) |
Smoking history | ||||
Never-smoker | 28 (82.4%) | 220 (83.7%) | 45 (80.4%) | 200 (84.4%) |
Current-smoker or ex-smoker | 3 (8.8%) | 27 (10.3%) | 4 (7.1%) | 26 (11.0%) |
Missing | 3 (8.8%) | 16 (6.1%) | 7 (12.5%) | 11 (4.6%) |
Diabetes mellitus (pre-existing and gestational) | 0 (0.0%) | 12 (4.6%) | 3 (5.4%) | 9 (3.8%) |
Medications before conception | 0 (0.0%) | 2 (0.8%) | 0 (0.0%) | 2 (0.8%) |
Medications during pregnancy | 0 (0.0%) | 10 (3.8%) | 3 (5.4%) | 7 (3.0%) |
Chorioamnionitis | 5 (14.7%) | 15 (5.7%) | 10 (17.9%) | 10 (4.2%) |
Antihypertensive medications (all) | 9 (26.5%) | 35 (13.3%) | 15 (26.8%) | 26 (11.0%) |
Only RASi | 4 (11.8%) | 28 (10.6%) | 9 (16.1%) | 21 (8.9%) |
Medications other than RASi | 5 (14.7%) | 7 (2.7%) | 6 (10.7%) | 5 (2.1%) |
Glucocorticoid therapy (all) | 4 (11.8%) | 29 (11.0%) | 6 (10.7%) | 27 (11.4%) |
DIV | 1 (2.9%) | 7 (2.7%) | 1 (1.8%) | 7 (3.0%) |
PO | 4 (11.8%) | 28 (10.6%) | 6 (10.7%) | 26 (11.0%) |
